SAN DIEGO, Nov. 21, 2017 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced a change to the company's presentation
time at the Evercore ISI Biopharma Catalyst/Deep Dive Conference in
Boston.
Marty Duvall, chief executive
officer, will now present at 1:35 p.m.
ET on Wednesday, November 29.
The live audio webcast from the conference and subsequent replay
may be accessed by visiting Tocagen's website. The
webcast will be available shortly after conclusion of the
presentation and archived on the company's website for 90 days
following the presentation.
About Tocagen
Tocagen is a clinical-stage,
cancer-selective gene therapy company developing first-in-class,
broadly applicable product candidates designed to activate a
patient's immune system against their own cancer. Tocagen is
developing its lead investigational product candidate, Toca 511
& Toca FC, initially for the treatment of recurrent high-grade
glioma (HGG), a disease with significant unmet medical need. The
U.S. Food and Drug Administration (FDA) has granted Toca 511 &
Toca FC Breakthrough Therapy Designation for the treatment of
recurrent HGG and the European Medicines Agency (EMA) has granted
Toca 511 PRIME (PRIority MEdicines) designation for the treatment
of HGG.
View original content with
multimedia:http://www.prnewswire.com/news-releases/tocagen-announces-time-change-for-presentation-at-evercore-isi-biopharma-catalystdeep-dive-conference-300559988.html
SOURCE Tocagen Inc.